This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 6 of 18 for:    Tysabri | Recruiting, Not yet recruiting, Available Studies

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis (NAPPREMS)

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Bianca Weinstock-Guttman, State University of New York at Buffalo
Sponsor:
Information provided by (Responsible Party):
Bianca Weinstock-Guttman, State University of New York at Buffalo
ClinicalTrials.gov Identifier:
NCT03046251
First received: February 3, 2017
Last updated: NA
Last verified: February 2017
History: No changes posted
  Purpose
The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

Condition Intervention Phase
Multiple Sclerosis Drug: Natalizumab Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Other
Official Title: Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Bianca Weinstock-Guttman, State University of New York at Buffalo:

Primary Outcome Measures:
  • Annualized Relapse Rate (ARR) [ Time Frame: 48 weeks ]
    The primary endpoint is the annualized relapse rate (ARR) during 1 year post-delivery in patients treated with natalizumab. This will be compared to the ARR in the parallel control group.


Secondary Outcome Measures:
  • Confirmed (12 week) EDSS change [ Time Frame: 48 weeks ]
    Confirmed (12 week) EDSS change of 1 point or more for a baseline EDSS > 1, or a confirmed increase of 1.5 points for an EDSS of 0-1, at Week 48 as compared to baseline between the 2 groups

  • AUC-EDSS changes [ Time Frame: 48 weeks ]
    AUC-EDSS changes from baseline to week 48 between the groups

  • Change in MRI [ Time Frame: 48 weeks ]
    Change in MRI: MRI at Week 48 for: new or enlarging T2, and T1 gadolinium-enhancing (GdE) lesions counts compared to the change in MRI control group

  • Time to first relapse [ Time Frame: 48 weeks ]
    Time to first relapse postpartum will be evaluated and compared between the 2 groups.

  • Percent of relapse free patients [ Time Frame: 48 weeks ]
    Percent of relapse free patients between the groups

  • Percent of patient that discontinued their DMT [ Time Frame: 48 weeks ]
    Percent of patient that discontinued their DMT initiated post-partum


Other Outcome Measures:
  • Change in QOL measures [ Time Frame: 48 weeks ]
    Change in QOL measures that will include: SF12v2, FSMC and MSIS-29 v2 from baseline to week 24 and 48 as compared to the control group.


Estimated Enrollment: 100
Actual Study Start Date: August 2015
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
natalizumab
Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
Drug: Natalizumab
No Intervention: Control
Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.

Detailed Description:

Postpartum patients with a diagnosis of multiple sclerosis (MS) will be given the opportunity to enroll in this study that will evaluate the efficacy of IV natalizumab to prevent postpartum relapses. Natalizumab, administered as 300mg IV q 4 weeks, will be initiated postpartum (0-30 days post-delivery).

Patients who decline natalizumab treatment postpartum will be given the opportunity to enroll in the study in the control group. The control group will have similar inclusion and exclusion criteria as well as scheduled visit and study procedures as the active natalizumab treatment group.

The primary objective of the trial is to assess the efficacy of IV administered natalizumab, monthly for 1 year, in preventing relapses during the postpartum period.

The secondary objectives of the trial are to assess the efficacy of natalizumab in decreasing the risk for disability progression during the postpartum period and to prevent the appearance of new and/or enlarging brain MRI lesions as measured by qualitative MRI analysis.

The tertiary objective is to assess the association of the clinical outcomes with subject evaluations including patient reported outcomes.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female subjects postpartum, 0-30 days postpartum at the time of informed consent.
  2. Diagnosis of relapsing form of MS.
  3. Willing to initiating natalizumab and enroll in the TOUCH system.
  4. Willing and able to comply with the study procedures for the duration of the trial.
  5. Signed informed consent and HIPAA authorization.

Exclusion Criteria:

  1. Diagnosis of primary progressive MS.
  2. Breastfeeding
  3. Use of IVIG in Tysabri treated subjects.
  4. Significant renal or hepatic impairment (in the opinion of the investigator) or other significant disease (e.g., cognitive impairment) that would compromise adherence and completion of the trial.
  5. History of hypersensitivity to previous exposure or presence of antibodies to natalizumab.
  6. Any other factor that, in the opinion of the investigator, would make the subject unsuitable for participation in this study.
  7. Patients that experience relapses and/or initiated DMT's during pregnancy

The Control group will consist of relapsing MS patients post-delivery who decline natalizumab therapy but open to enroll in the study.

Similar Inclusion and Exclusion criteria as the natalizumab group with the exception of requiring TOUCH enrollment program. The Control group will be allowed to initiate any FDA approved DMT at any time post delivery or remain on no therapy while breastfeeding.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03046251

Contacts
Contact: Kara Patrick 716-859-7510 kpatrick@buffalo.edu

Locations
United States, New York
SUNY Buffalo Recruiting
Buffalo, New York, United States, 14203
Contact: Kara Patrick    716-859-7510    kpatrick@buffalo.edu   
Sponsors and Collaborators
State University of New York at Buffalo
Investigators
Principal Investigator: Bianca Weinstock-Guttman, MD SUNY Buffalo
  More Information

Responsible Party: Bianca Weinstock-Guttman, Professor of Neurology, State University of New York at Buffalo
ClinicalTrials.gov Identifier: NCT03046251     History of Changes
Other Study ID Numbers: US-TYS-14-10720
Study First Received: February 3, 2017
Last Updated: February 3, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Natalizumab
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 27, 2017